PATENT CLAIM ANALYSIS

Application Number: 16062602
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "252040"]

Abstract:
The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

Claim (Index 12):
The compound according to  claim 1 , an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein said atropisomer is a P atropisomer.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 94.0
- Lexical Diversity: 1.51163
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16062606', '15554801', '14302337', '14920833', '16319783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7762021881097341
- 35 USC 102 Novelty (BERT): 0.5828554056602557
- Combined Prediction Score: 0.7568675098647862
- Mean Citation Score: 374.356734
- Max Citation Score: 464.61694000000006
- Similarity Product: 426.3443457666003

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test